FibroBiologics, Inc. Common Stock (FBLG) NASDAQ

0.73

-0.0154(-2.06%)

Updated at June 25 11:37AM

Currency In USD

FibroBiologics, Inc. Common Stock

Address

455 East Medical Center Boulevard

Houston, DE 77598

United States of America

Phone

281 651 5150

Sector

Healthcare

Industry

Biotechnology

Employees

13

First IPO Date

February 01, 2024

Key Executives

NameTitlePayYear Born
Mr. Peter O'HeeronFounder, Chairperson & Chief Executive Officer1.02M1964

Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.